A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients

Metformin is a first-line medication for type 2 diabetes mellitus (T2DM). Based on its universal use, the consideration of inter-individual variability and development of predictive biomarkers are clinically significant. We aimed to identify endogenous markers of metformin responses using a pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong-Eun, Jeong, Gui-Hwa, Lee, In-Kyu, Yoon, Young-Ran, Liu, Kwang-Hyeon, Gu, Namyi, Shin, Kwang-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100517/
https://www.ncbi.nlm.nih.gov/pubmed/29966242
http://dx.doi.org/10.3390/molecules23071579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100517/
https://www.ncbi.nlm.nih.gov/pubmed/29966242
http://dx.doi.org/10.3390/molecules23071579

Ejemplares similares